Answers are grounded in this paper and cite their sources.
This review highlights how metal complexes influence cytotoxicity in cancer treatments, indicating potential for improved efficacy over cisplatin.
After more than half a century since the discovery of cisplatin's antitumor activity, the unwanted effects of chemotherapy have not been overcome. Developing a metal complex with improved activity and reduced toxicity compared to cisplatin still remains a challenge. It is well known that the nature of bridging ligands in dinuclear metal complexes determines their binding to DNA and thus strongly influences their cytotoxicity. However, designing a metal complex that is more active and less toxic than cisplatin is still not an easy task. Understanding the influence of central metal ions as well as that of coordinated ligands in dinuclear metal complexes is therefore crucial. In this short review, dinuclear platinum(II) and palladium(II) complexes with different nitrogen-donor ligands are presented. This review provides an overview of how the structure of dinuclear platinum(II) and palladium(II) complexes affects their binding to key physiological biomolecules (DNA, BSA, and AChE), with emphasis on their cytotoxicity.
No takes yet. Share an insight, caveat, or question.
Franich et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: